Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Monte Rosa Therapeutics Inc GLUE

Healthcare Biotechnology
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GLUE)

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

GlobeNewswire 3 days ago

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

GlobeNewswire 12 days ago

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 24, 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

GlobeNewswire January 10, 2025

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2025

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

GlobeNewswire December 13, 2024

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire December 11, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

GlobeNewswire December 11, 2024

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

GlobeNewswire December 5, 2024
View More News ››

Opinion & Analysis (NDAQ:GLUE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GLUE)

The MoBot Report

Just In: $GLUE The MoBot Report2024-10-28 12:33:06 ET DENVER, Colo., Oct 28, 2024 ( 247marketnews.com )- MoBot@s recent alerts involved;...
whytestocks - October 28, 2024

Monte Rosa Therapeutics' AI And Machine Learning Platform Is

NEWS: $GLUE Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research...
whytestocks - February 15, 2024
View more Bullboard ››

G Mining Ventures Corp.

G Mining Ventures Corp.

G Mining Ventures Corp. is a Canada-based mining company. The Company is engaged in the acquisition, exploration and ...
View More »